Brief: Statera Biopharma And Immune Therapeutics Inc. Announce Strategic Agreement For Rights To Low Dose Naltrexone
27/04/2022 21:28
April 27 (Reuters) - Statera Biopharma STAB.O :
* STATERA BIOPHARMA AND IMMUNE THERAPEUTICS INC. ANNOUNCE
STRATEGIC AGREEMENT FOR RIGHTS TO LOW DOSE NALTREXONE
* STATERA BIOPHARMA INC- STATERA WILL RECEIVE AN INITIAL $2
MILLION UPFRONT PAYMENT AND 5% OF ISSUED AND OUTSTANDING STOCK
OF IMMUNE THERAPEUTICS
* STATERA BIOPHARMA INC- TRANSACTION HAS ABILITY TO GENERATE
OVER
$400 MILLION IN NON-DILUTIVE PAYMENTS TO STATERA
Source text for Eikon: ID:nGNX4kJRFG
Further company coverage: STAB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biostax
See all newsBrief: Biostax Corp Announces Voluntary Delisting From Otc Pink Market And SEC Deregistration
Brief: Biostax Corp. And Statera Biopharma Inc Reach Mutually Beneficial Dispute Settlement And Amended License Agreement Providing Clearer Clinical And Commercial Pathways For Both Companies
Brief: Immune Therapeutics Inc Announces Management Change
Brief: Statera Biopharma And Immune Therapeutics Inc. Announce Strategic Agreement For Rights To Low Dose Naltrexone
Brief: Immune Therapeutics Today Announces Appointment Of Michael Handley As Its New Chief Executive Officer And Member Of The Board Of Directors